Zura Bio Limited
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for immune and inflammatory disorders in the United States. The company develops Tibulizumab, an immunoglobulin G-single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes interleukin (IL)-17A and B-cell activating factor, which is in Phase 2 … Read more
Market Cap & Net Worth: Zura Bio Limited (94E)
Zura Bio Limited (F:94E) has a market capitalization of $360.42 Million (€351.13 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #17406 globally and #1815 in its home market, demonstrating a -6.09% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Zura Bio Limited's stock price €5.40 by its total outstanding shares 65023308 (65.02 Million).
Zura Bio Limited Market Cap History: 2026 to 2026
Zura Bio Limited's market capitalization history from 2026 to 2026. Data shows growth from $360.42 Million to $360.42 Million (0.00% CAGR).
Zura Bio Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Zura Bio Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 94E by Market Capitalization
Companies near Zura Bio Limited in the global market cap rankings as of March 19, 2026.
Key companies related to Zura Bio Limited by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Zura Bio Limited Historical Marketcap From 2026 to 2026
Between 2026 and today, Zura Bio Limited's market cap moved from $360.42 Million to $ 360.42 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €360.42 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Zura Bio Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $360.42 Million USD |
| MoneyControl | $360.42 Million USD |
| MarketWatch | $360.42 Million USD |
| marketcap.company | $360.42 Million USD |
| Reuters | $360.42 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.